Scotland R&D plant
This article was originally published in The Tan Sheet
Executive Summary
Mentholatum announces plans to create a state-of-the-art research and development center in East Kilbride, Scotland. The firm has already invested $20 million, which will increase production capacity at the plant owned by Mentholatum's Japan-based parent company, Rohto Pharmaceutical. Mentholatum says it "aims to cement its position as a market leader in the eye, lip and personal care categories and grow its presence in the skincare market on the back of its acquisition of the high-profile Oxy brand." Mentholatum acquired the brand from GlaxoSmithKline in December 2004 (1"The Tan Sheet" Dec. 20, 2004, p. 8)...